Stock A170900 DONG-A ST CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Dong-A ST Co., Ltd.

Equities

A170900

KR7170900005

Pharmaceuticals

End-of-day quote Korea S.E.
Other stock markets
 06:00:00 2024-07-11 pm EDT 		5-day change 1st Jan Change
69,100 KRW +3.44% Intraday chart for Dong-A ST Co., Ltd. +1.32% 0.00%
Jun. 25 NeuroBo Pharmaceuticals, Inc. announced that it has received $17.000005 million in funding from Dong-A ST Co., Ltd. CI
Jun. 23 NeuroBo Pharmaceuticals, Inc. announced that it expects to receive $17.000005 million in funding from Dong-A ST Co., Ltd. and other investors CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 1,004,168 747,641 604,345 523,481 597,946 601,247 - -
Enterprise Value (EV) 2 968.7 745.6 713.4 615.5 812.5 790.6 734.4 690.8
P/E ratio 15.5 x 27 x 52.1 x 61 x 36.4 x 15.3 x 16.3 x 9.62 x
Yield 0.84% 1.13% 1.4% 1.15% 1.01% 1.11% 1.11% 1.05%
Capitalization / Revenue 1.64 x 1.27 x 1.02 x 0.82 x 0.99 x 0.91 x 0.88 x 0.81 x
EV / Revenue 1.58 x 1.27 x 1.21 x 0.97 x 1.34 x 1.2 x 1.07 x 0.93 x
EV / EBITDA 12.6 x 13.8 x 20.2 x 12.1 x 13.8 x 13.1 x 10.7 x 7.88 x
EV / FCF 22.2 x -74.2 x -56.4 x -64.5 x -294 x 12.2 x 15.7 x 8.63 x
FCF Yield 4.5% -1.35% -1.77% -1.55% -0.34% 8.22% 6.37% 11.6%
Price to Book 1.55 x 1.16 x 0.97 x 0.76 x 0.88 x 0.94 x 0.9 x 0.81 x
Nbr of stocks (in thousands) 8,779 8,779 8,782 8,782 8,653 8,701 - -
Reference price 3 114,379 85,160 68,820 59,608 69,100 69,100 69,100 69,100
Announcement Date 2/12/20 2/3/21 2/8/22 2/13/23 3/18/24 - - -
1KRW in Million2KRW in Billions3KRW
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 612.2 586.6 590.1 635.8 605.2 660.3 683.9 741.4
EBITDA 1 77.05 54 35.34 51.02 59.05 60.56 68.92 87.65
EBIT 1 57 34.06 15.49 30.53 32.71 30.4 48.6 64.65
Operating Margin 9.31% 5.81% 2.63% 4.8% 5.4% 4.6% 7.11% 8.72%
Earnings before Tax (EBT) 1 83.1 33.84 11.34 13.55 21.39 51 48.9 81
Net income 1 65 27.65 11.97 9.02 17.3 39.8 37.82 63
Net margin 10.62% 4.71% 2.03% 1.42% 2.86% 6.03% 5.53% 8.5%
EPS 2 7,400 3,150 1,320 976.5 1,897 4,528 4,244 7,181
Free Cash Flow 3 43,572 -10,050 -12,657 -9,542 -2,767 65,000 46,767 80,000
FCF margin 7,117.31% -1,713.33% -2,144.85% -1,500.73% -457.21% 9,844.01% 6,837.83% 10,790.4%
FCF Conversion (EBITDA) 56,550.61% - - - - 107,331.57% 67,856.45% 91,272.1%
FCF Conversion (Net income) 67,034.1% - - - - 163,316.58% 123,639.57% 126,984.13%
Dividend per Share 2 961.2 961.2 961.2 686.3 700.0 764.9 764.9 725.9
Announcement Date 2/12/20 2/3/21 2/8/22 2/13/23 3/18/24 - - -
1KRW in Billions2KRW3KRW in Million
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 149.9 153.5 160.2 158.3 163.8 135.1 154.1 150.2 165.7 140.1 163.2 168.7 178.4 157.6 164.1
EBITDA 1 - - - 15.45 9.347 - 9.854 19.57 12.58 7.093 7.2 17.9 23.6 - -
EBIT 1 -4.861 7.887 4.317 14.17 4.149 6.682 8.753 13.08 4.197 0.735 0.9 11.6 17.2 8.9 9.7
Operating Margin -3.24% 5.14% 2.69% 8.96% 2.53% 4.94% 5.68% 8.7% 2.53% 0.52% 0.55% 6.88% 9.64% 5.65% 5.91%
Earnings before Tax (EBT) 1 -8.252 7.247 4.503 22.17 -20.38 11.72 6.178 14.76 -11.26 2.115 17.5 20.4 0.9 14.9 15.5
Net income 1 -5.755 2.291 3.831 24.04 -17.55 9.132 4.813 11.5 -8.143 1.71 13.6 15.9 0.7 11.6 12.1
Net margin -3.84% 1.49% 2.39% 15.19% -10.71% 6.76% 3.12% 7.65% -4.91% 1.22% 8.34% 9.43% 0.39% 7.36% 7.37%
EPS - - - - - - - - - - - - - - -
Dividend per Share - - - - - - - - - - - - - - -
Announcement Date 2/8/22 4/27/22 7/27/22 10/26/22 2/13/23 4/27/23 7/27/23 10/31/23 3/18/24 5/2/24 - - - - -
1KRW in Billions
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - 109 92 215 189 133 89.6
Net Cash position 1 35.5 2 - - - - - -
Leverage (Debt/EBITDA) - - 3.087 x 1.803 x 3.634 x 3.127 x 1.933 x 1.022 x
Free Cash Flow 2 43,572 -10,050 -12,657 -9,542 -2,767 65,000 46,767 80,000
ROE (net income / shareholders' equity) 10.5% 2.5% 1.83% 1.35% 2.59% 4.48% 5.3% 7.65%
ROA (Net income/ Total Assets) 6.6% 1.62% 1.14% 0.8% 1.47% 2.65% 3.25% 4.3%
Assets 1 985.4 1,707 1,050 1,125 1,179 1,502 1,164 1,465
Book Value Per Share 3 73,987 73,631 71,135 78,078 78,160 73,618 76,748 84,833
Cash Flow per Share 3 6,412 3,071 5,221 3,740 2,479 5,531 5,862 -
Capex 1 12.7 37 61.1 44.1 23.8 29.7 12.1 15.1
Capex / Sales 2.08% 6.31% 10.35% 6.93% 3.93% 4.5% 1.77% 2.03%
Announcement Date 2/12/20 2/3/21 2/8/22 2/13/23 3/18/24 - - -
1KRW in Billions2KRW in Million3KRW
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Dong-A ST Co., Ltd.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Specialty & Advanced Pharmaceuticals

1st Jan change Capi.
DONG-A ST CO., LTD. Stock Dong-A ST Co., Ltd.
0.00% 438M
MERCK KGAA Stock Merck KGaA
+7.04% 73.13B
KYOWA KIRIN CO. LTD. Stock Kyowa Kirin Co. Ltd.
+31.10% 10.38B
YUHAN CORPORATION Stock Yuhan Corporation
+37.94% 5.16B
SK BIOPHARMACEUTICALS CO., LTD. Stock SK Biopharmaceuticals Co., Ltd.
-17.33% 4.73B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD. Stock Shenyang Xingqi Pharmaceutical Co.,Ltd.
+21.49% 3.81B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD. Stock Shanghai Shyndec Pharmaceutical Co., Ltd.
+24.92% 2.26B
BETTA PHARMACEUTICALS CO., LTD. Stock Betta Pharmaceuticals Co., Ltd.
-36.84% 1.88B
CHANGCHUN BCHT BIOTECHNOLOGY CO. Stock Changchun BCHT Biotechnology Co.
-43.31% 1.77B
VELOXIS PHARMACEUTICALS A/S Stock Veloxis Pharmaceuticals A/S
-0.50% 1.64B
Specialty & Advanced Pharmaceuticals
  1. Stock Market
  2. Equities
  3. A170900 Stock
  4. Financials Dong-A ST Co., Ltd.